Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  2. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  4. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  5. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  6. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  7. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  8. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  9. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  10. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  11. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  12. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  13. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  14. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  15. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  16. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  17. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  18. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  19. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  20. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  21. Healy LM, et al. 2020. Glia. 68:811. PubMed
  22. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  23. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  24. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  25. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  26. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  27. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  28. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  29. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  30. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  31. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  32. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  33. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  34. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  35. Price P, et al. 2014. J Virol. 88:10840. PubMed
  36. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  37. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  38. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  39. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  40. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  41. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  42. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  43. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  44. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  45. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  46. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  47. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  48. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  49. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  50. Toomer G, et al. 2022. Viruses. 14:. PubMed
  51. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  52. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  53. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  54. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  55. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  56. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  57. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  58. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  59. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  60. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  61. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  62. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  63. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  64. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  65. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  66. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  67. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  68. Munoz MA, et al. 2021. Elife. 10:. PubMed
  69. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  70. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  71. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  72. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  73. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  74. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  75. Yu X, et al. 2021. Nature. 594:560. PubMed
  76. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  77. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  78. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  79. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  80. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  81. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  82. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  83. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  84. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  85. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  86. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  87. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  88. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  89. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  90. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  91. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  92. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  93. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  94. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  95. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  96. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  97. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  98. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  99. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  100. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  101. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  102. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  103. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  104. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  105. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  106. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  107. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  108. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  109. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  110. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  111. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  112. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  113. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  114. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  115. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  116. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  117. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  118. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  119. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  120. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  121. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  122. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  123. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  124. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  125. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  126. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  127. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  128. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  129. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  130. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  131. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  132. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  133. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  134. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  135. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  136. Köchl R, et al. 2020. Elife. 9:00. PubMed
  137. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  138. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  139. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  140. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  141. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  142. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  143. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  144. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  145. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  146. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  147. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  148. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  149. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  150. Romine KA, et al. 2021. Cancer Discov. . PubMed
  151. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  152. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  153. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  154. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  155. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  156. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  157. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  158. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  159. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  160. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  161. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  162. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  163. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  164. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  165. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  166. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  167. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  168. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  169. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  170. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  171. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  172. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  173. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  174. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  175. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  176. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  177. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  178. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  179. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  180. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  181. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  182. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  183. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  184. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  185. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  186. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  187. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  188. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  189. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  190. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  191. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  192. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  193. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  194. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  195. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  196. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  197. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  198. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  199. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  200. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  201. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  202. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  203. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  204. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  205. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  206. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  207. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  208. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  209. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  210. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  211. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  212. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  213. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  214. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  215. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  216. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  217. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  218. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  219. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  220. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  221. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  222. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  223. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  224. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  225. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  226. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  227. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  228. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  229. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  230. Barington L, et al. 2022. Cells. 11:. PubMed
  231. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  232. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  233. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  234. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  235. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  236. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  237. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  238. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  239. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  240. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  241. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  242. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  243. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  244. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  245. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  246. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  247. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  248. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  249. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  250. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  251. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  252. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  253. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  254. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  255. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  256. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  257. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  258. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  259. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  260. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  261. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  262. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  263. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  264. Kumar S, et al. 2022. Gut. . PubMed
  265. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  266. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  267. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  268. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  269. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  270. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  271. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  272. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  273. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  274. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  275. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  276. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  277. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  278. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  279. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  280. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  281. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  282. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  283. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  284. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  285. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  286. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  287. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  288. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  289. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  290. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  291. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  292. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  293. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  294. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  295. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  296. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  297. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  298. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  299. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  300. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  301. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  302. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  303. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  304. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  305. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  306. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  307. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  308. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  309. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  310. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  311. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  312. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  313. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  314. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  315. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  316. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  317. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  318. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  319. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  320. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  321. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  322. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  323. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  324. Yuan C, et al. 2018. iScience. 11:13. PubMed
  325. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  326. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  327. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  328. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  329. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  330. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  331. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  332. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  333. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  334. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  335. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  336. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  337. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  338. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  339. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  340. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  341. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  342. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  343. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  344. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  345. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  346. Spath S, et al. 2022. iScience. 25:104998. PubMed
  347. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  348. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  349. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  350. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  351. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  352. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  353. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  354. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  355. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  356. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  357. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  358. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  359. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  360. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  361. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  362. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  363. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  364. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  365. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  366. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  367. Chiou SH, et al. 2021. Immunity. 54:586. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?
Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.
I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use your Zombie dyes for microscopy application?

Zombie dyes that have been tested for microscopy applications in-house will display data on the product webpage. It should be noted that Zombie may not work for dead cell discrimination in every microscopy application, as a complicated point will be to determine the level of Zombie signal that constitutes a dead cell. Another difficulty may be finding the proper plane for microscopy in order to observe the dead cells.

Why can't I fix my cells prior to using Zombie?

The fixation process can contort and alter the membrane of cells, effectively rendering them as dead. Since the ability of Zombie to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie and Annexin V to detect apoptotic cells?

Yes, Zombie can be used with Annexin V to discriminate live, apoptotic, and dead cells. Cells double positive for both Zombie and Annexin V are dead, while Zombie-dim/Annexin V-positive cells are apoptotic. Live cells will be Zombie-low and Annexin V-negative. The advantage to Zombie over PI and 7-AAD is that you can now fix and/or permeabilize the cells to stain for cell surface and intracellular antigens.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


Go To Top Version: 8    Revision Date: 01-27-2021

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account